EZZ Life Science Holdings Ltd. (EZZ) AI Stock Analysis

• Market Cap: AU$105.20M
• Dividend Yield: 2.35%
• Average Volume (3M): 49.70K
• Price to Earnings (P/E): 15.3
• Beta (1Y): 0.53
• Revenue Growth: 0.65%
• EPS Growth: -9.90%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 47,173,200
• 10 Day Avg. Volume: 67,551
• 30 Day Avg. Volume: 49,696
• PEG Ratio: -2.57
• Price to Book (P/B): 3.85
• Price to Sales (P/S): 1.62
• P/FCF Ratio: 26.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: AU$2.00 ▲(17.65% Upside)

EZZ Life Science Holdings Ltd. has a strong financial foundation with high profitability and a solid balance sheet. However, technical indicators suggest bearish momentum, and recent declines in revenue and cash flow growth pose challenges. The valuation is moderate, offering some income potential but not enough to offset the current technical weaknesses.

Positive Factors

Strong Profit Margins

High profit margins indicate efficient operations and pricing power, allowing EZZ to maintain profitability despite market fluctuations.

Robust Balance Sheet

A strong balance sheet with minimal debt enhances financial stability and provides flexibility for strategic investments and growth.

Multi-Channel Distribution

A diversified distribution strategy broadens market reach and reduces dependency on a single sales channel, supporting revenue stability.

Negative Factors

Decline in Revenue Growth

A decline in revenue growth could indicate market saturation or increased competition, potentially impacting long-term growth prospects.

Cash Flow Challenges

Challenges in cash flow generation may limit the company's ability to fund operations and invest in growth opportunities, affecting future performance.

Volatile Revenue Growth Rate

Volatility in revenue growth can create uncertainty in financial planning and may deter long-term investors seeking stable returns.

EZZ Life Science Holdings Ltd. Business Overview & Revenue Model

Company Description

EZZ Life Science Holdings Limited provides skin care and consumer health products in Australia, New Zealand, Mainland China, and internationally. The company operates in two segments, Brought in Lines and Company Owned products. It is involved in the wholesale distribution of EAORON branded skin care products to pharmacies, supermarkets, and specialist retailers, as well as grocery retailers. The company also designs, develops, produces, distributes, and sells consumer health products, including vitamins and dietary supplements, sports nutrition, weight management and wellbeing, herbal/traditional, and paediatric products under the EZZ brand through its e-commerce platforms and stores, such as Tmall Global. EZZ Life Science Holdings Limited was incorporated in 2015 and is based in Silverwater, Australia.

How the Company Makes Money

EZZ generates revenue through the sale of its dietary supplements and health products, which are marketed both online and through retail partnerships. The company employs a multi-channel distribution strategy, leveraging e-commerce platforms and traditional retail outlets to reach a broad audience. Key revenue streams include direct-to-consumer sales via their website and partnerships with health and wellness retailers. Additionally, EZZ may engage in strategic collaborations with other companies in the health sector to expand its product offerings and market reach, contributing to its overall earnings.

EZZ Life Science Holdings Ltd. Financial Statement Overview

Summary

EZZ Life Science Holdings Ltd. demonstrates strong profitability and a solid balance sheet with minimal leverage. However, recent declines in revenue and free cash flow growth highlight potential challenges in sustaining growth.

Income Statement

EZZ Life Science Holdings Ltd. shows strong profitability with a consistent gross profit margin above 70% and a net profit margin around 10%. However, the revenue growth rate has been volatile, with a significant decline of 10.88% in the latest year. Despite this, EBIT and EBITDA margins remain healthy, indicating efficient operations.

Balance Sheet

The company maintains a very low debt-to-equity ratio, indicating minimal leverage risk. Return on equity is robust, reflecting effective use of equity to generate profits. The equity ratio is solid, suggesting a strong capital structure with a high proportion of assets financed by equity.

Cash Flow

Cash flow metrics indicate some challenges, with a significant decline in free cash flow growth recently. The operating cash flow to net income ratio is below 1, suggesting potential issues in converting income into cash. However, the free cash flow to net income ratio is close to 1, showing that free cash flow generation is relatively aligned with net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	66.87M	66.87M	66.44M	37.14M	15.02M	22.29M
Gross Profit	49.72M	49.72M	50.95M	27.20M	7.51M	12.46M
EBITDA	10.08M	11.10M	10.38M	5.09M	1.90M	2.87M
Net Income	6.73M	6.73M	6.96M	3.63M	1.31M	2.03M
Balance Sheet
Total Assets	33.96M	33.96M	25.55M	17.64M	14.27M	12.04M
Cash, Cash Equivalents and Short-Term Investments	20.85M	20.85M	19.02M	13.83M	10.46M	8.85M
Total Debt	304.49K	304.49K	123.86K	478.59K	104.57K	79.01K
Total Liabilities	5.87M	5.87M	4.23M	3.06M	2.88M	1.93M
Stockholders Equity	28.09M	28.09M	21.32M	14.58M	11.39M	10.11M
Cash Flow
Free Cash Flow	4.13M	4.09M	5.73M	3.91M	1.89M	237.42K
Operating Cash Flow	4.37M	4.35M	6.14M	4.01M	1.90M	253.53K
Investing Cash Flow	-546.93K	-546.93K	-441.17K	-101.78K	-13.18K	-16.12K
Financing Cash Flow	-2.17M	-2.17M	-582.45K	-761.72K	-277.36K	5.44M

EZZ Life Science Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Negative. The current price of 1.7 is below the 20-day moving average (MA) of 2.30, below the 50-day MA of 2.47, and below the 200-day MA of 2.04, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 23.33 is Positive, neither overbought nor oversold. The STOCH value of 2.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EZZ.

EZZ Life Science Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	60 Neutral	AU$105.20M	15.29	27.24%	2.35%	0.65%	-9.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RCE	48 Neutral	AU$141.70M	-5.44	―	―	―	0.66%
ATX	46 Neutral	AU$69.26M	―	-27.39%	―	―	26.64%
ATH	41 Neutral	AU$108.75M	―	-42.68%	―	―	63.46%
IMU	41 Neutral	$108.79M	―	-83.09%	―	―	55.94%
ALA	40 Underperform	AU$106.68M	-13.09	-47.98%	―	700.00%	26.88%

EZZ Life Science Holdings Ltd. Corporate Events

EZZ Life Science Declares Final Dividend for 2025

EZZ Life Science Holdings Limited has announced a fully franked final dividend of $0.020 per share for the fiscal year ending 30 June 2025. The dividend will be paid on 23 December 2025, with an ex-dividend date of 24 November 2025 and a record date of 25 November 2025. This announcement reflects the company’s commitment to rewarding shareholders and may enhance its attractiveness to investors.

The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Expands Market Reach and Product Line Amidst Financial Challenges

EZZ Life Science Holdings Limited reported its quarterly activities and financials for Q1 FY26, highlighting strategic progress in market expansion and product innovation. The company made significant strides in the US market by shifting its marketing strategy towards performance-driven campaigns and expanding its retail channels, including discussions to enter the Walmart Marketplace. Domestically, EZZ expanded its pharmacy network and launched a new Shopify store to boost its retail presence in Australia. Despite a 25.4% drop in customer receipts due to deferred payments and seasonal factors in China, EZZ maintained a strong cash position of $17.3 million and remains debt-free. The company launched three new health products, reinforcing its competitive edge and commitment to innovation. Looking forward, EZZ aims to scale its brand in the US, drive growth in Southeast Asia, and continue expanding its Australian retail channels.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Holdings Ltd. Announces 2025 AGM with Digital Access

EZZ Life Science Holdings Ltd. has announced its Annual General Meeting (AGM) scheduled for November 28, 2025. The company will provide meeting materials electronically, following recent legislative changes, to enhance accessibility and environmental sustainability. Shareholders are encouraged to participate and submit their votes in advance through various online and offline channels.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Holdings Ltd. Announces Annual General Meeting Agenda

EZZ Life Science Holdings Ltd. has announced its Annual General Meeting to be held on November 28, 2025. Key agenda items include the consideration of financial statements, the adoption of the remuneration report, the re-election of director Glenn Cross, and the approval of a mandate to issue equity securities. These resolutions are significant as they impact the company’s governance and capital structure, potentially influencing shareholder value and strategic direction.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Sets AGM Date and Director Nomination Deadline

EZZ Life Science Holdings Limited has announced the date for its 2025 Annual General Meeting, which will be held on November 28, 2025. The company has also set October 17, 2025, as the closing date for director nominations. This announcement is part of EZZ’s ongoing efforts to strengthen its governance and strategic positioning in the genomic life sciences sector.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.

EZZ Life Science Reports Resilient Financial Performance Amidst Market Challenges

EZZ Life Science Holdings Ltd. reported a slight increase in revenue by 0.65% to $66.87 million for the year ending June 2025, while profits decreased by 3.36% to $6.73 million. Despite the decline in profit, the company saw an increase in net assets and share capital, indicating a strengthening financial position. The dividends remained consistent with the previous year, reflecting stable shareholder returns. These financial results suggest a resilient performance amidst challenging market conditions, potentially impacting stakeholder confidence positively.

The most recent analyst rating on (AU:EZZ) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.